पुर्तगाल - पुर्तगाली - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

takeda pharmaceuticals international ag ireland branch - messalazina - comprimido gastrorresistente de libertação prolongada - 1200 mg - messalazina 1200 mg - mesalazine - n/a - duração do tratamento: longa duração

यूरोपीय संघ - पुर्तगाली - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - esclerose múltipla - imunossupressores seletivos - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

ब्राज़ील - पुर्तगाली - ANVISA (Agência Nacional de Vigilância Sanitária)

natulab laboratÓrio s.a - Ácido fÓlico - antianemicos simples

ब्राज़ील - पुर्तगाली - ANVISA (Agência Nacional de Vigilância Sanitária)

natulab laboratÓrio s.a - Ácido fÓlico - antianemicos simples

ब्राज़ील - पुर्तगाली - ANVISA (Agência Nacional de Vigilância Sanitária)

pharlab indÚstria farmacÊutica s.a. - digoxina - glicosideos cardiacos

ब्राज़ील - पुर्तगाली - ANVISA (Agência Nacional de Vigilância Sanitária)

farmoquÍmica s/a - Ácido fÓlico - antianemicos

ब्राज़ील - पुर्तगाली - ANVISA (Agência Nacional de Vigilância Sanitária)

pfizer brasil ltda - palbociclibe - antineoplasico

यूरोपीय संघ - पुर्तगाली - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

यूरोपीय संघ - पुर्तगाली - EMA (European Medicines Agency)

novartis europharm limited - asciminib hydrochloride - leucemia, myélogênico, crônico, bcr-abl positivo - agentes antineoplásicos - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

यूरोपीय संघ - पुर्तगाली - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - esclerose múltipla remitente-recorrente envio - imunossupressores - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).